These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19429869)

  • 41. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
    Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
    Schneider F; Hoster E; Unterhalt M; Schneider S; Dufour A; Benthaus T; Mellert G; Zellmeier E; Bohlander SK; Feuring-Buske M; Buske C; Braess J; Fritsch S; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Hiddemann W; Spiekermann K
    Blood; 2009 May; 113(21):5250-3. PubMed ID: 19279329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size.
    Nomdedeu J; Bussaglia E; Villamor N; Martinez C; Esteve J; Tormo M; Estivill C; Queipo MP; Guardia R; Carricondo M; Hoyos M; Llorente A; Juncà J; Gallart M; Domingo A; Bargay J; Mascaró M; Moraleda JM; Florensa L; Ribera JM; Gallardo D; Brunet S; Aventin A; Sierra J;
    Leuk Res; 2011 Feb; 35(2):163-8. PubMed ID: 20542566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
    How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
    Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nucleophosmin gene mutations in acute myeloid leukemia.
    Chen W; Rassidakis GZ; Medeiros LJ
    Arch Pathol Lab Med; 2006 Nov; 130(11):1687-92. PubMed ID: 17076533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.
    Garg S; Reyes-Palomares A; He L; Bergeron A; Lavallée VP; Lemieux S; Gendron P; Rohde C; Xia J; Jagdhane P; Müller-Tidow C; Lipka DB; Imren S; Humphries RK; Waskow C; Vick B; Jeremias I; Richard-Carpentier G; Hébert J; Sauvageau G; Zaugg JB; Barabé F; Pabst C
    Blood; 2019 Jul; 134(3):263-276. PubMed ID: 31076446
    [No Abstract]   [Full Text] [Related]  

  • 50. MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status.
    Faraoni I; Laterza S; Ardiri D; Ciardi C; Fazi F; Lo-Coco F
    J Hematol Oncol; 2012 Jun; 5():26. PubMed ID: 22681934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute Myeloid Leukaemia with Gene Mutation: A Correlation with Haematological and Immunophenotypic Characteristics and Our Experience in a Tertiary Care Cancer Center in South India.
    Khera R; Ahmed F; Mundada M; Nambaru L; Murthy SS; Devig S; Rajappa SJ; Mallavarapu KM; Santa A; Kumar P
    Turk Patoloji Derg; 2018; 34(2):171-174. PubMed ID: 28984348
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
    Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Correlation of NPM1, FLT3-ITD mutations with leukocyte count and myeloblasts percentage in AML patients with normal karyotype].
    Su L; Li W; Cui JW; Tan YH; Yang Y; Liu XL; Yu P; Hu RP; Wang LL; Gao SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):571-5. PubMed ID: 23815900
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
    Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
    Verhaak RG; Goudswaard CS; van Putten W; Bijl MA; Sanders MA; Hugens W; Uitterlinden AG; Erpelinck CA; Delwel R; Löwenberg B; Valk PJ
    Blood; 2005 Dec; 106(12):3747-54. PubMed ID: 16109776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
    Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
    Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. miRNA-mRNA Profiling Reveals Prognostic Impact of
    Gadewal N; Kumar R; Aher S; Gardane A; Gaur T; Varma AK; Khattry N; Hasan SK
    Oncol Res; 2020 May; 28(3):321-330. PubMed ID: 32059753
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.
    Rau R; Brown P
    Hematol Oncol; 2009 Dec; 27(4):171-81. PubMed ID: 19569254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.